A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Asthma

Interventions

DRUG: Frevecitinib
DRUG: Placebo

Sponsor

Kinaset Therapeutics Inc